Literature DB >> 1692862

Target antigens of transmission blocking immunity of Plasmodium vivax malaria. Characterization and polymorphism in natural parasite isolates.

S Premawansa1, J S Peiris, K L Perera, G Ariyaratne, R Carter, K N Mendis.   

Abstract

A panel of 20 anti-Plasmodium vivax female gamete mAb has been established and was characterized with respect to their transmission-blocking properties in membrane-feeding experiments and their target Ag identified. Seven mAb suppressed the infectivity of P. vivax parasites to Anopheles tesselatus mosquitoes. The m.w. of the Ag recognized by these mAb were ascertained by SDS-PAGE and Western blots. Three sets of polypeptides of low Mr--20, 24, and a doublet of 37/42 kDa--have been defined as target Ag of transmission-blocking antibodies of P. vivax. All epitopes of these target Ag were found to be dependent on the tertiary conformational structure of the Ag. Polymorphism of target Ag of transmission-blocking immunity was investigated in over 30 natural isolates of P. vivax in Sri Lanka based on the reactivity of a mAb with an isolate as assessed by the indirect immunofluorescent test with the use of live extracellular female gametes, and in Western blots with the use of extracted gametes. The functional consequences of antigenic polymorphism on immunity was investigated in transmission-blocking assays by using membrane-feeding experiments. A majority of target Ag of transmission-blocking immunity were found to be polymorphic, exhibiting size as well as epitope polymorphism. Results indicate that failure of a mAb to affect the infectivity of a parasite isolate of P. vivax to mosquitoes can be caused by polymorphism of the target Ag among isolates.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1692862

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

1.  Characterization of Plasmodium vivax transmission-blocking activity in low to moderate malaria transmission settings of the Colombian Pacific coast.

Authors:  Myriam Arévalo-Herrera; Yezid Solarte; Leonardo Rocha; Diego Alvarez; John C Beier; Sócrates Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

2.  Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes.

Authors:  H Hisaeda; A W Stowers; T Tsuboi; W E Collins; J S Sattabongkot; N Suwanabun; M Torii; D C Kaslow
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

3.  Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates.

Authors:  T Tsuboi; D C Kaslow; M M Gozar; M Tachibana; Y M Cao; M Torii
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

4.  Tumour necrosis factor-dependent parasite-killing effects during paroxysms in non-immune Plasmodium vivax malaria patients.

Authors:  N D Karunaweera; R Carter; G E Grau; D Kwiatkowski; G Del Giudice; K N Mendis
Journal:  Clin Exp Immunol       Date:  1992-06       Impact factor: 4.330

Review 5.  Immunity against sexual stage Plasmodium falciparum and Plasmodium vivax parasites.

Authors:  Roos M de Jong; Surafel K Tebeje; Lisette Meerstein-Kessel; Fitsum G Tadesse; Matthijs M Jore; Will Stone; Teun Bousema
Journal:  Immunol Rev       Date:  2019-12-16       Impact factor: 12.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.